The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
August 15th 2025
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.
Health Outcomes Under Full-Risk Medicare Advantage vs Traditional Medicare
Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
Read More
This study compared 6 algorithmic fairness–improving approaches for low-birth-weight predictive models and found that they improved accuracy but decreased sensitivity for Black populations.
Read More
HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations
May 9th 2025A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor resistance or adverse reactions, although clinicians may struggle with determining the ideal patient population.
Watch
Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials
May 9th 2025A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.
Watch
Final Thoughts Alzheimer Disease Care
May 9th 2025Panelists discuss how the current Alzheimer disease treatment landscape represents both significant progress with novel amyloid-targeting therapies and ongoing challenges, while expressing hope for future advances including more potent disease-modifying treatments, combination therapies, earlier intervention capabilities, improved biomarkers, greater health care equity, and comprehensive care models that address both medical and psychosocial aspects of the disease.
Watch
Analyzing Treatment-Refractory Patients
Panelists discuss how managing bronchiectasis exacerbations involves targeted antibiotics based on sputum cultures, augmenting mucus clearance with devices, and considering surgical intervention when medical management fails.
Watch
Exploring the Impact of Bronchiectasis Exacerbations
Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.
Watch
Effect of Remote Patient Monitoring on Stage 2 Hypertension
May 6th 2025A community-based remote patient monitoring (RPM) program was associated with significant reduction in blood pressure in Medicare patients with stage 2 hypertension, highlighting the potential benefits of RPM with care coaching.
Read More
Longitudinal, Relationship-Based Case Management: A Prospective Cohort Trial
A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year.
Read More
Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
Watch
Emerging Therapies: Other Strategies and Important Considerations
May 5th 2025Panelists discuss how targeted therapies for immunoglobulin A (IgA) nephropathy are advancing rapidly, with promising results from trials of B-cell modulating agents that inhibit APRIL/BAFF signaling and complement pathway inhibitors that address specific steps in the 4-hit cascade.
Watch
Comprehensive Molecular Testing in Patients With Ovarian Cancer
May 5th 2025A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
Watch
Emerging Molecular Biomarkers in Ovarian Cancer
May 5th 2025A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are emerging as important for guiding ovarian cancer therapy, including microsatellite instability (MSI), tumor mutational burden (TMB), HER2, p53, KRAS, and CCNE amplification.
Watch
From AAD 2025 to the Future: Advancements in Dermatology to Watch
May 5th 2025A panelist discusses how the evolving landscape of atopic dermatitis treatment is moving toward a more personalized approach that carefully balances efficacy goals with safety considerations, incorporating new targeted therapies alongside traditional options while also expressing excitement about emerging research in dermatology including novel bispecific antibodies, microbiome-based interventions, and noninvasive diagnostic technologies that may revolutionize disease management in the coming years.
Watch
The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
Watch
Emerging Anti-BAFF and Anti-APRIL Therapies
May 5th 2025Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by specifically addressing the underlying pathophysiology of the 4-hit cascade rather than broadly suppressing inflammation.
Watch
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO
May 2nd 2025To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Read More